केवल अनुपस्थिति दौरों के साथ बाल्यकालीन अनुपस्थिति मिर्गी का उपचार

References

The treatment of choice for CAE with absence seizures only is ethosuximide.

Therefore, based on the CAE trial, ETX is the drug of choice as initial monotherapy for CAE, when absence seizures are the only seizure type, but there are specific treatment considerations for each drug, which are discussed below.

The initial target dosage of ETX is 20–30 mg/kg/day, usually divided into two doses. The initial dosage is typically around 10 mg/kg/day, with upward titration to the target every week.

The primary outcome measure was freedom from failure, defined as the absence of clinically apparent seizures (based on parent report) or electrographic seizures at 16–20 weeks of treatment, and the absence of treatment-limiting adverse effects.